NCT01356290 2026-02-23
MEMMAT
Medical University of Vienna
Phase 2 Recruiting
Clinical Trials
10 trialsNCT06528691 2026-02-17
Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors
St. Jude Children's Research Hospital
Phase 2 Recruiting
NCT05535166 2026-02-12
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
St. Jude Children's Research Hospital
Phase 2 Recruiting
NCT06528496 2026-02-10
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05762419 2026-01-28
FUS Etoposide for DMG
Columbia University
Phase 1 Recruiting
NCT05106296 2026-01-09
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
Augusta University
Phase 1 Recruiting
NCT02605421 2025-10-21
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
Masonic Cancer Center, University of Minnesota
Phase 2 Recruiting
NCT04765098 2025-06-26
Tamoxifen Versus Etoposide After First Recurrence in GBM Patients
AHS Cancer Control Alberta
Phase 2 Recruiting
NCT04501718 2024-10-15
Apatinib Combined with Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children
Beijing Sanbo Brain Hospital
Phase 2 Recruiting
NCT01704716 2020-10-23
High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
St. Anna Kinderkrebsforschung
Phase 3 Recruiting